Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.

J Clin Endocrinol Metab · 2022 · PMC9202729 · PMID 35275196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Analysis of the urinary alloTHF/THF ratio, a marker of the 5α/5β reductase activity, showed a trend for a small reduction at 90 days in patients receiving AZD4017, with an estimated adjusted-for-baseline treatment effect of −0.19 (95% CI: −0.34, −0.04).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.